Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meropenem vs Standard Antibiotics in Secondary Nosocomial Sepsis
NCT00318552Phase 4Completed
- Sponsor
- Pfizer
- Start
- Jan 2002
- Primary completion
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of meropenem in sepsis (2 arms), sponsored by Pfizer. Primary endpoints: Number of days from randomization to recovery from sepsis and Reduction in time to recovery from sepsis considering mortality. Started Jan 2002; status: completed.
02
Drugs
meropenem
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT00318552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00318552.